Sort
48,018 grants matching “immunotherapy”
Cellular Processing Core
$389,384Victor M Lemas · Johns Hopkins University · P01 · FY2011 · CA
Immune Activating CAR-Modified Antigen Presenting Cells
$389,375Carl Deselm · Washington University · DP5 · FY2018 · OD
Monitoring neurochemical signaling dynamics in the lymph node
$389,361Ashley E Ross · University Of Cincinnati · R01 · FY2023 · AI
Pharmacokinetics and Immunodynamics of Immune stimulating chemotherapeutic nanoparticles for TB
$389,355Jessica L Reynolds · State University Of New York At Buffalo · R01 · FY2018 · AI
Project 2: Optimal Targeting of the PD-1/PD-L1 Pathway in MRCC
$389,350Catherine Ju-Ying Wu · Beth Israel Deaconess Medical Center · P50 · FY2023 · CA
Studies of Inherited Causes of Fungal Susceptability
$389,291Sergio Rosenzweig · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI
Generating CTL Against Tumor Associated Peptide Antigens
$389,284Linda A Sherman · Scripps Research Institute, The · R01 · FY2012 · CA
Generating CTL Against Tumor Associated Peptide Antigens
$389,284Linda A Sherman · Scripps Research Institute, The · R01 · FY2011 · CA
The genomic landscape and evolution of cutaneous squamous cell carcinoma
$389,263Alan Hunter Shain · University Of California, San Francisco · R01 · FY2024 · CA
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
$389,250Fred Hutchinson Cancer Research Center · R01 · FY2001 · CA
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
$389,250Fred Hutchinson Cancer Research Center · R01 · FY2003 · CA
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
$389,250Fred Hutchinson Cancer Research Center · R01 · FY2000 · CA
NOVEL THERAPEUTIC STRATEGIES IN MYELODYSPLASTIC SYNDROME
$389,250Fred Hutchinson Cancer Research Center · R01 · FY2002 · CA
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
$389,221Jeffrey Victor Ravetch · Sloan-Kettering Inst Can Research · P01 · FY2017 · CA
Role of Ly6K in TGF-beta and immune escape pathways of triple negative breast cancer
$389,208Geeta Upadhyay · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2019 · CA
Preclinical Study of Peptide Based Human Tumor Vaccines
$389,164University Of Virginia Charlottesville · R01 · FY2005 · CA
Core C: Correlative Sciences PDCS/TCSL
$389,123Simon F Lacey · University Of Pennsylvania · P01 · FY2020 · CA
Subcellular enzyme-instructed self-assembly for molecular anticancer nanomedicines
$389,109Bing Xu · Brandeis University · R01 · FY2022 · CA
(8) Genetics of Immune Related Adverse Events and Response to Immunotherapy
$389,055Elad Ziv · University Of California, San Francisco · R01 · FY2020 · CA
Development
$389,054Ramanuj Dasgupta · New York University School Of Medicine · P30 · FY2010 · CA
REVERSING IMMUNOTHERAPY RESISTANCE IN OVARIAN CANCER BY TARGETING A NOVEL IMMUNE-SUPPRESSIVE FACTOR RELEASED BY TUMOR-ASSOCIATED MACROPHAGES (TAMS)
$388,999Mainehealth · · FY2017 · Department of the Army
PROTECTION DURING GRAM NEGATIVE BACTERIAL SEPSIS
$388,955University Of Minnesota Twin Cities · R01 · FY2002 · GM
Cell Penetrating Helical Peptide Inhibitors of vFLIP K13
$388,922Preet M. Chaudhary · University Of Southern California · R01 · FY2014 · DE
Cell Penetrating Helical Peptide Inhibitors of vFLIP K13
$388,922Preet M. Chaudhary · University Of Southern California · R01 · FY2012 · DE
Antibody-Targeted NK Cell Activation for Cancer Therapy
$388,916Fox Chase Cancer Center · R01 · FY2003 · CA